Clinical Trial Detail

NCT ID NCT04464759
Title A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (LIMIT)
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ravi Amaravadi, MD
Indications

melanoma

Therapies

Nivolumab

Hydroxychloroquine + Ipilimumab + Nivolumab

Hydroxychloroquine + Nivolumab

Age Groups: adult senior

No variant requirements are available.